Turkish Journal of Medical Sciences
Volume 41

Number 3

Article 12

1-1-2011

Potential role of some nutraceuticals in the regression of
Alzheimer’s disease in an experimental animal model
HANAA HAMDY AHMED
WAFAA GHONEIM SHOUSHA
REHAB MAHMOUD HUSSIEN
ABDEL RAZIK HUSSEIN FARRAG

Follow this and additional works at: https://journals.tubitak.gov.tr/medical
Part of the Medical Sciences Commons

Recommended Citation
AHMED, HANAA HAMDY; SHOUSHA, WAFAA GHONEIM; HUSSIEN, REHAB MAHMOUD; and FARRAG,
ABDEL RAZIK HUSSEIN (2011) "Potential role of some nutraceuticals in the regression of Alzheimer’s
disease in an experimental animal model," Turkish Journal of Medical Sciences: Vol. 41: No. 3, Article 12.
https://doi.org/10.3906/sag-0907-136
Available at: https://journals.tubitak.gov.tr/medical/vol41/iss3/12

This Article is brought to you for free and open access by TÜBİTAK Academic Journals. It has been accepted for
inclusion in Turkish Journal of Medical Sciences by an authorized editor of TÜBİTAK Academic Journals. For more
information, please contact academic.publications@tubitak.gov.tr.

Original Article

Turk J Med Sci
2011; 41 (3): 455-466
© TÜBİTAK
E-mail: medsci@tubitak.gov.tr
doi:10.3906/sag-0907-136

Potential role of some nutraceuticals in the regression of
Alzheimer’s disease in an experimental animal model
Hanna Hamdy AHMED1, Wafaa Ghoneim SHOUSHA2, Rehab Mahmoud HUSSIEN2,
Abdel Razik Hussein FARRAG3

Aim: The goal of this study was to evaluate the potential role of some nutraceuticals, coenzyme Q10, vitamin B complex,
and lecithin against aluminum-induced neurodegeneration characteristic of Alzheimer’s disease.
Materials and methods: Ninety-six male and female Sprague Dawley rats were divided into 2 main groups, namely
female and male. Each group was divided into 6 subgroups. Group 1 served as control group. Group 2 was administered
AlCl3 for 4 months. Groups 3, 4, 5, and 6 were administered with AlCl3 for 4 months then treated with Coenzyme Q10,
vitamin B complex, lecithin, or all in combination for 3 months, respectively. Brain acetylcholinesterase (AChE), Na+/K+ATPase activities, and vitamin B12, folate, homocysteine (Hcy), lipid peroxidation, glutathione, and plasma nitric oxide
(NO) levels were determined. Moreover, histopathological examination of brain tissue was evaluated.
Results: Al intoxication caused a significant increase in brain AChE activity, Hcy, lipid peroxidation, and plasma NO
levels, while it produced significant decrease in brain Na+/K+-ATPase activity, glutathione, vitamin B12, and folate levels.
Moreover, histopathological investigation of the brain of Al intoxicated rats showed marked neurodegeneration and
deposition of neurofibrillary tangles. Treatment with the selected nutraceuticals revealed an improvement in the
neurological damage induced by AlCl3 as indicated by improvement in most of the biochemical markers and
histopathological features.
Conclusion: The selected nutraceuticals (Coenzyme Q10, vitamin B complex, lecithin, and their combination) may play
a beneficial role in delaying the progression of neurodegenerative disorders. It is noteworthy that the combined therapy
revealed more pronounced effect compared to singular treatments with either one of them.
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Introduction
Aluminum (Al) is the third most abundant element and the most common metal in the earth’s
crust (1). With the global industrialization and consequent pollution, Al is increasingly taken into
our bodies through food, air, water, and even drugs (2). Al is present in many manufactured foods
and is added as alum for treating drinking water for purification purposes (3,4).
Aluminum (Al) is considered as a potential etiological factor in Alzheimer’s disease (AD) (5,6).
Excessive Al intake might lead to deposition of Aβ in central nerve cells and overexpression of βamyloid precursor protein (APP) (7,8). The neurotoxicity of Aβ is associated with oxidative stress
(9) and with the generation of reactive oxygen species that damage neuronal membrane, lipids,
proteins, and nucleic acids. Acetylcholinesterase (AChE) has been found to colocalize with Aβ
deposits and promotes the assembly of Aβ into amyloid fibrils forming Aβ-AChE complex that is
more toxic than amyloid fibrils (10).
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Nutrition plays an important role in the treatment
of many diseases, and the right choice of nutrients can
help to prevent disorders and improve the quality of
life. The future challenge will be to combine the
strategic use of both cosmeceuticals and
nutraceuticals in preventing the damaging effects of
ultraviolet radiation and environmental pollutants on
many biologic processes (11-13).
Coenzyme Q10 is a fat-soluble-vitamin like
quinone commonly known as ubiquinone, CoQ, and
vitamin Q10. The efficacy of Co Q10 appears most
promising for alleviating neurodegenerative disorders
(14).
Vitamin B12 plays a role in the pathogenesis of
behavioral changes in AD (15). Vitamin B12 deficiency
could aggravate or accelerate the course of AD as it
possesses neuroprotective and anti-inflammatory
properties (16). Vitamin B1 (thiamine) plays an
important role against brain damage. The progress of
damage can be stopped by a timely injection of a large
dose of thiamine (17).
Lecithin is the major dietary source of choline and,
in some circumstances, it can be transformed into
ACh (18). Extra consumption of lecithin may reduce
the progression of dementia (19). Therefore, this
study aimed to investigate the potential role of some
nutraceuticals, namely coenzyme Q10, vitamin B
complex, and lecithin, against aluminum induced
neurodegeneration characteristic of Alzheimer’s
disease.
Materials and methods
Nutraceuticals
Coenzyme Q10 was obtained from Arab Co. for
Pharmaceuticals and Medicinal Plants (MEPACO),
Egypt. Vitamin B complex was purchased from
Global Napi Pharmaceutical. Egypt. Lecithin was
provided by Techno Pharma, Egypt.
Animals
Ninety six (male and female) Sprague Dawley aged
rats supplied by the Animal Laboratory House of the
National Research Centre, Cairo, Egypt. They were
kept in a regulated environment (25 ± 1 °C, 50 ± 2%
humidity), with 12 h light/dark cycles. Animal
Laboratory Administrative Center and the
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Institutional Ethics Committee at the National
Research Centre, Cairo, Egypt, approved all the
experimental procedures.
Experimental design
The animals were divided into 2 main groups,
namely female and male. Each group was subdivided
into 6 groups. Group 1 served as control group. Group
2 was administered AlCl3 (100 mg kg-1 b.w.) (20) for 4
months. Groups 3, 4, 5, and 6 were administered AlCl3
for 4 months, and then treated with either one of
-1
Coenzyme Q10, (200 mg kg b.w.) (21); vitamin B
-1
-1
complex (0.2 mg kg b.w.) (22); lecithin (60 mg kg
b.w.) (23), or all in combination for 3 months. AlCl3
and the nutraceuticals were given orally using gastric
tube.
At the end of the experiment period, fasting blood
samples were collected from retro-orbital venous
plexus under diethyl ether anesthesia. Blood samples
were collected in heparinized tubes and then
centrifuged at 3000 rpm at 4 °C for 15 min to separate
plasma, which were used for nitric oxide (NO)
determination.
After blood collection, the brains of the rats were
dissected, washed in isotonic saline, and dried. Each
brain was mid-sagittally divided into 2 portions. The
first portion was fixed in formalin buffer for
histopathological investigation. The second portion
of brain was weighed and homogenized immediately
to give 10% (w/v) homogenate in ice-cold medium
containing 50 mM Tris-HCl and 300 mM sucrose.
The homogenate was centrifuged at 3000 rpm for 10
min in cooling centrifuge at 4 °C. The supernatant
(10%) was used for determination of
+
+
acetylcholinesterase activity (AChE), Na /K -ATPase
activity, and reduced glutathione (GSH), vitamin B12
and folate as well as homocysteine levels. The
supernatant (10%) was further diluted to give 5% for
determination of lipid peroxidation level.
Biochemical examinations:
A kinetic spectrophotometric method was used to
+
+
determine AChE activity (24). The Na /K -ATPase
activity was determined according to the method
described by Tsakiris et al. (25). Lipid peroxidation
was estimated according to Satoh (26). GSH level was
determined according to the method of Ellman (27).
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Determination of plasma nitric oxide (NO) was
carried out according to the method of Berkels et al.
(28). Determination of brain vitamin B12 and folate
were carried out using radioimmunoassay (RIA)
technique (29). Homocysteine levels were measured
using the method of Frantzen et al. (30).
Histopathological investigation
Brain samples were fixed in buffered formalin
solution for 1 week. Then, the brain tissues were
washed in running tap water for 24 h, and dehydrated
in ascending series of alcohol. The samples were
cleared in xylene and immersed in paraffin. The
tissues were mounted in blocks and left at 4 °C until
the time to be used. The paraffin blocks were
sectioned at 5 μm thickness and mounted on clean
glass slides. Ordinary hematoxylin and eosin stain was
used (31).
Statistical analysis
The obtained data were presented as mean ±
standard error. The difference between 2 groups was
calculated using independent Student’s t-test, while
the difference between more than 2 groups was
calculated using one way analysis of variance
(ANOVA) using MSTAT-C version 4 program
according to Snedecor and Cochran (32).

Results
The present study showed that aluminum induced
a significant increase in brain AChE while it caused a
significant decrease in Na+/K+-ATPase activities (P <
0.01) compared to the control group in both genders.
Treatment with either CoQ10, vitamin B, or lecithin
alone or all in combination showed a significant
decrease (P < 0.01) in brain AChE activity in both
female and male rats compared to Al-intoxicated
group. On the other hand, Na+/K+-ATPase activity
showed a significant increase in each of CoQ10,
vitamin B, lecithin (P < 0.05), and in the combined
therapy groups (P < 0.01) compared to the Alintoxicated group (Table 1).
Al produced a significant elevation in brain AChE
activity in the Al-intoxicated group compared to the
other 5 groups [control, CoQ10, vitamin B complex,
lecithin, and the combination therapy (CoQ10 +
lecithin + vitamin B)], whereas it caused a significant
inhibition in brain Na+/K+-ATPase activity compared
to the same 5 groups. Insignificant change in the
activity of the 2 enzymes was detected among the
treated groups except the presence of a significant
elevation in Na+/K+-ATPase activity in the combined
therapy-treated group compared to vitamin B or
lecithin-treated groups in both female and male rats
(Table 1).

Table 1. Brain acetylcholinesterase and Na+/K+-ATPase activities among the groups.
Acetylcholinesterase
(U/mg protein)

+

+

Na /K -ATPase
(μmol pi/h/mg protein)

Parameters
Groups

Female

Male

Female

Male

Control

518 ± 29.0

415 ± 39.5

7.1 ± 0.37

6.6 ± 0.48

Al intoxication

906 ± 14.0*

600 ± 21.8*

3.6 ± 0.15*

3.2 ± 0.13*

Al→CoQ10

680 ± 24.7**

469 ± 14.6**

5.2 ± 0.53**

4.4 ± 0.42**

Al→Vitamin B complex

666 ± 14.0**

470 ± 15.4**

5.0 ± 0.18**

4.3 ± 0.32**

Al→Lecithin

700 ± 24.7**

487 ± 26.0**

4.5 ± 0.14**

4.0 ± 0.21**

Al→(CoQ10 + Vit.B + lecithin)

653 ± 2.80**

446 ± 12.7**

6.0 ± 0.36**

5.1 ± 0.27**

* Significant difference at P < 0.05 as compared with the control group.
** Significant difference at P < 0.05 as compared with the Al intoxicated group.
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Concerning brain vitamin B12, folate, and
homocysteine levels, the results revealed a significant
decrease (P < 0.01) in brain vitamin B12 and folate levels
and a significant increase (P < 0.01) in homocysteine
level in Al- intoxicated group compared to the control
group in both genders. Moreover, there was a significant
increase in vitamin B12 level among CoQ10, vitamin B
complex, combined therapy (P < 0.01), or lecithintreated group (P < 0.05) compared to the Al-intoxicated
group in both genders. Treatment with CoQ10, vitamin B
complex, lecithin, or the combined therapy revealed a
significant increase (P < 0.01) in folate levels in both
genders compared to the Al-intoxicated group, whereas
it showed a significant decrease (P < 0.01) in
homocysteine levels in both female and male rats
compared to the Al-intoxicated group (Table 2).
The comparison between all groups showed that
Al administration revealed significant variations in
vitamin B12, folate, and homocysteine levels among
the other 5 groups in both genders. Al produced a
significant inhibition in brain vitamin B12 and folate
levels in the Al-intoxicated group compared to the
other 5 groups, whereas it produced a significant
increase in brain Hcy levels compared to the same 5
groups. There was a significant change in vitamin B12
and folate levels among the treated groups except in
the combination therapy-treated group where there
was no significant change in vitamin B12 and folate
levels compared to the vitamin B complex-treated

group in both female and male rats. Furthermore,
treatment with CoQ10 showed an insignificant change
in vitamin B12 levels in both female and male rats and
in folate levels in male rats as compared to the
lecithin-treated group. The obtained data revealed a
significant change in homocysteine levels among the
treated groups except in the CoQ10-treated group
where there was an insignificant change in Hcy levels
compared to the vitamin B complex-treated group in
both male and female rats. In addition, there was an
insignificant change in Hcy levels in the combined
therapy-treated group compared to the CoQ10-treated
group in male rats (Table 2).
The results showed a significant increase (P < 0.01)
in each of brain lipid peroxidation and plasma nitric
oxide levels in the Al-intoxicated group compared to
the control group in both female and male rats.
Treatment with CoQ10, vitamin B complex, lecithin,
or the combined therapy showed a significant
decrease (P < 0.01) in brain lipid peroxidation and
plasma nitric oxide levels in both female and male rats
compared to the Al-treated group. Brain glutathione
levels showed a significant decrease in the Alintoxicated group as compared to the control group
in both female and male rats. Treatment with CoQ10,
vitamin B complex, lecithin, or the combined therapy
revealed a significant increase (P < 0.01) in brain
glutathione levels in both female and male rats
compared to the Al-intoxicated group (Table 3).

Table 2. Brain vitamin B12, folate, and homocysteine levels among the groups.
Vitamin B12
(pg/mg protein)

Folate
(ng/mg protein)

Homocystein
(μmol/mg protein)

Parameters
Groups

Female

Control

110.3 ± 2.6

Male

Female

Male

Female

Male

109.3 ± 2.3

1.6 ± 0.08

1.6 ± 0.08

5.4 ± 0.14

6.5 ± 0.0 4

10.1 ± 0.01*

10.6 ± 0.17*

Al intoxication

76.7 ± 2.6*

72.8 ± 2.7*

0.8 ± 0.04*

0.8 ± 0.03*

Al→CoQ10

92.2 ± 3.5**

89.2 ± 3.8**

1.2 ± 0.02**

1.1 ± 0.05**

6.5 ± 0.12**

7.5 ± 0.14**

Al→Vitamin B complex

98.9 ± 1.6**

94.0± 2.9**

1.4 ± 0.06**

1.3 ± 0.05

6.9 ± 0.23**

8.2 ± 0.01**

Al→Lecithin

84.6 ± 2.2**

86.4± 1.2**

1.0 ± 0.02**

1.0 ± 0.04**

7.5 ± 0.27**

7.8 ± 0.08**

102.6 ± 2.6**

98.7 ± 2.3**

1.4 ± 0.05**

1.3± 0.05

6.1 ± 0.07**

7.4 ± 0.12**

Al→(CoQ10 + Vit.B + lecithin)

* Significant difference at P < 0.05 as compared with the control group.
** Significant difference at P < 0.05 as compared with the Al intoxicated group.
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Table 3. Brain lipid peroxidation, glutathione, and plasma nitric oxide levels among the groups.
Nitric oxide
(μmol/L)

Glutathione
(μmol/mg protein)

Lipid Peroxidation
(nmol/mg protein)

Parameters
Groups

Female

Male

Female

Control

30.8 ± 0.9

30.8 ± 0.9

0.31 ± 0.03

Al intoxication

42.7 ± 1.7*

42.7 ± 1.7*

Al→CoQ10

34.6 ± 0.75**

Al→Vitamin B complex

Male

Female

Male

0.39 ± 0.02

4.9 ± 0.2

4.8 ± 0.35

0.10 ± 0.01*

0.26 ± 0.02*

7.9 ± 0.2*

7.6 ± 0.27*

34.6 ± 0.75**

0.23 ± 0.01**

0.39 ± 0.01**

5.6 ± 0.2**

5.5 ± 0.32**

36.4 ± 0.40**

36.4 ± 0.40**

0.26 ± 0.01** 0.37 ± 0.01**

6.1 ± 0.15**

5.9 ± 0.26**

Al→Lecithin

34.3 ± 1.6**

34.3 ± 1.6**

0.17 ± 0.01** 0.30 ± 0.02**

5.7 ± 0.35**

5.5 ± 0.33**

Al→(CoQ10 + Vit.B + lecithin)

32.7 ± 0.96**

32.7 ± 0.96**

0.27 ± 0.02** 0.39 ± 0.02**

5.2 ± 0.36**

5.2 ± 0.40**

* Significant difference at P < 0.05 as compared with the control group.
** Significant difference at P < 0.05 as compared with the Al intoxicated group.

The results showed that Al administration caused
a significant variation in brain lipid peroxidation,
glutathione, and plasma nitric oxide levels among the
other 5 groups (P < 0.01). Al causes a significant
elevation in brain lipid peroxidation and plasma nitric
oxide compared to the other 5 groups whereas it
caused a significant decrease in brain glutathione level
compared to other 5 groups in both female and male
rats. There was an insignificant change in brain lipid
peroxidation level among the 4 treated groups in both
male and female rats. There is an insignificant change
in plasma nitric oxide level among the 3 of the treated
groups in both female and male rats except in the
combined therapy-treated group where there was a
significant change in plasma nitric oxide level
compared to the vitamin B complex-treated group in
both female and male rats. Furthermore, there was a
significant change in brain glutathione levels in the
lecithin-treated group compared to the other treated
groups in both female and male rats (Table 3).
Histopathological investigation
The microscopic examination of the brain sections
of control female and male rats showed highly active
nerve cells having huge nuclei with relatively palestain. The nuclear chromatin and prominent nucleoli
are dispersed. The surrounding relatively inactive
supporting cells have small nuclei with densely-stain,
condensed chromatin, and no visible nucleoli (Figures
1A and 2A).

Supplementation with AlCl3 for 4 months in both
female and male rats showed necrosis of the brain and
deposition of neurofibrillary tangles. The normal
structure and outlines of the nerve cells and their
nucleoli are lost. Some neurons appeared like a ring
shape (Figures 1B and 2B). Examination of brain
sections of both male and female rats intoxicated with
AlCl3 and treated with CoQ10 for 3 months showed
necrosis of few neurons. The normal structure and the
outlines of the nerve cells and their nuclei appeared
(Figures 1C and 2C).
Following the administration of vitamin B
complex for 3 months after AlCl3 intoxication, the
neurons revealed a healthy appearance with smallcondensed surrounding cells. Necrosis of some
neurons still appeared (Figures 1D and 2D).
Brain sections of female and male rats treated with
lecithin after AlCl3 intoxication showed that the nuclei
of the nerve cells were shifted to the periphery. The
supporting cells were condensed and surrounded by a
shadow-like ring in female rats (Figures 1E and 2E).
The histopathological investigation of the brain
sections of the rats supplemented with the combined
therapy (CoQ10, vitamin B complex, and lecithin) after
AlCl3 intoxication showed more or less normal
neurons in both female and male rats except the
appearance of pale supporting cells in both male and
female rats (Figures 1F and 2F).
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B
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D

E
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Figure 1. Photomicrographs of brain sections of female rats. (A) Control, shows nerve cells having huge nuclei
with relatively pale-stain (arrow) and the supporting cells have small nuclei with densely-stain (arrowhead), (B) Al intoxicated rat shows necrosis of the brain (arrow) and deposition of neurofibrillary
tangles (arrowhead). Some neurons appeared like ring shape (*), (C) Al→ CoQ10, shows necrosis of
few neurons (arrow), (D) Al→ Vit.B12, the neurons reveal healthy appearance with small-condensed surrounding cells. Necrosis of some neurons still appeared (arrow). (E) Al→ Lecithin and shows that the
nuclei of the nerve cells were shifted to the periphery. The supporting cells were condensed and surrounded by shadow like ring in female rats (arrow), (F) Al→ CoQ10, Vit.B12 and Lecithin shows more
or less normal neurons except the appearance of pale supporting cells (arrow) (H & E X 400).
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E

F

Figure 2. Photomicrographs of brain sections of male rats. (A) Control, shows nerve cells having huge nuclei with
relatively pale-stain (arrow) and the supporting cells have small nuclei with densely-stain (arrowhead);
(B) Al intoxicated rat shows necrosis of the brain (arrow) and deposition of neurofibrillary tangles
(arrowhead). Some neurons appeared like ring shape (*), (C) Al→ CoQ10, shows necrosis of few neurons (arrow (D) Al→ Vit.B12, the neurons reveal healthy appearance with small-condensed surrounding cells (arrow). Necrosis of some neurons still appeared (arrowhead) (E) Al→ Lecithin and (F) Al→
(CoQ10, Vit.B12 and Lecithin) shows more or less normal neurons except the appearance of pale supporting cells (arrow) (H & E X400).

Discussion
In view of the obtained data, long-term treatment
with AlCl3 caused elevation in the AChE activity. An
increase in AChE activity can explain that Al interacts

with the cholinergic system, acting as a cholinotoxin
(33). The interference with cholinergic projection
functions may represent the way by which Al
contributes to pathological processes in AD leading
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to learning and memory deficits (34). Besides the fact
that Al is a cholinotoxin agent, its neurotoxic effect
could be exerted by additional mechanisms, such as
induction of oxidative stress (4). The increased
production of the AChE may be due to a direct action
of Aβ, which binds to nicotinic receptors or over
expression of β-amyloid precursor (APP) and
consequently Aβ induced by Al results in the
increased activity of AChE within and around Aβ
plaques (35).
It was found that AChE increment in Al
intoxicated female rats was more than that in male.
For instance, estrogen efficiencies with advancing age
in woman lead to impaired mitochondrial enzymes
and were proposed as a key contributor to metabolic
imbalance in AD (36). This may help explain gender
differences in disease incidence and support a possible
use of steroid hormone therapy (37).
Gender may also influence the levels of
proinflammatory cytokines as older woman may have
low grade inflammation status as compared to older
male (38). On the other hand, Li et al. (39) found that
AD is more prevalent in female than male.
In the present study, Al administration caused a
reduction of brain Na+/K+ ATPase activity. Lynch et
al. (40) stated that self-aggregation of Aβ due to Al
administration leads to generation of hydrogen
peroxide and hydroxyl radical via certain chemical
reactions. The production of these reactive oxygen
species induces membrane lipid peroxidation, which
can impair the function of membrane ion-motive
ATPase (Na+/K+- and Ca+-ATPases) resulting in
membrane depolarization and a decrease in cellular
ATP levels.
The present data demonstrate that AlCl3 reduced
brain vitamin B12 and folate levels with concomitant
increase in brain homocysteine (Hcy) levels. Impaired
vitamin B12 functions and decreased vitamin B12 status
have been associated with neurological and cognitive
impairment (41). It has been suggested that folate
deficiency may precede AD and vascular dementia
(42). The suggested mechanism for decreasing
vitamin B12 in the present study is that Al potentiates
cerebral oxidative stress, which in turn augments the
oxidation of an intermediate form of vitamin B12 that
is generated in the methionine synthase reaction,
thereby impairing the metabolism of Hcy. Oxidative
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stress also compromises the intraneuronal reduction
of the vitamin to its metabolically active state (43).
Deficiencies of folate and vitamin B12 resulted in high
concentration of Hcy (44). Superphysiological levels
of Hcy are neurotoxic in cell culture and in vivo
mouse models (45). Accumulation of Hcy in the brain
leads to growth restriction, neural or cognitive
dysfunction (46), impaired brain energy metabolism,
and the inhibition of Na+/K+ ATPase activity (47).
The brain is an organ that is especially susceptible
to peroxide damage because of several factors, such
as its high lipid content, high oxygen turn over, low
mitotic rate as well as low antioxidant concentration.
However, increased production of reactive oxygen
species (ROS) was reported during Al exposure,
which is attributed to electron leakage and increased
electron chain activity (48). ROS subsequently attack
almost all cell components including membrane
lipids, producing lipid peroxidation (49). Thus, it can
be hypothesized that oxidative stress could be one of
the contributing factors for Al-induced central
nervous disorders (50). This explains the increased
brain lipid peroxidation levels in Al-intoxicated rats
in the current study.
The depletion of reduced glutathione (GSH) in the
brain of Al intoxicated rats in the current study may
be due to the effect of Al on GSH synthesis by
decreasing the activity of glutathione synthase (GS), a
rate-limiting step of whole reaction, thus leading to
reduced GSH content (51). A depletion of cellular
GSH can impair cellular defenses against the toxic
actions of ROS and other compounds that lead to
cellular injury and death (52).
Nitric oxide has been suggested to play multiple
roles in Al intoxication (53). Al could stimulate nitric
oxide production by activating inducible nitric oxide
synthase (iNOS) (54). Furthermore, Aβ upregulated
the cytokine-mediated induction of iNOS and altered
the cellular redox in glial cells (55). This explanation
suggests the role of peroxynitrite (ONOO-; a reaction
product of NO· and ·O2-)-mediated pathology in the
AD brain (56).
The present data showed that administration of
Coenzyme Q10 in Al-intoxicated rats revealed a
significant reduction in brain AChE activity, and
homocysteine, lipid peroxidation, and plasma nitric
levels where it led to a significant increase in each of
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+

+

brain Na /K ATPase activity, and vitamin B12, folate
and glutathione levels.
Coenzyme Q10 (CoQ10) is a well known
hydrophobic member of the mitochondrial electron
transport chain, which is capable of accepting either 1
or 2 electrons. CoQ10 acts as a potent natural
antioxidant, oxygen-derived free radical scavenger as
well as membrane stabilizer (57,58). CoQ10
participates as a cofactor of dehydrogenases in the
transport of electron and proton as well as in ATP
production, so it can stimulate ATPase activity (59).
CoQ10 is able to inhibit mitochondrial ROS generation
and inner mitochondrial depolarization as it has been
reported that supplementing the rats with diet
containing CoQ10 reduced ROS production in the
mitochondria (60). Moreover, Gomez-Diaz et al. (61)
stated that plasma membrane protection against
oxidative stress is increased due to CoQ10
supplementation. Based on the link between the rate
of Aβ production and induced oxidative stress, CoQ10
exerts its neuroprotective effect via reduction of
oxidative stress (62). Taken together, the abovementioned functions of CoQ10 permit this coenzyme
to exhibit an improvement in each of the biochemical
markers investigated in the present study.
Our results indicated that vitamin B complex
administration to Al-intoxicated rats resulted in a
significant improvement in the studied biochemical
parameters. This could be explained by the efficacy of
folate to decrease brain Al accumulation and
influence Al influx, efflux, or both from the brain
(63). There is a direct relation between folic acid
supplementation and Al accumulation so that folate
acts on intestinal Al absorption and the presence of
folate in the lumen inhibits the transport of Al. This
inhibition may occur by a folate–Al complex
formation (63). Moreover, the high level of total
homocysteine (tHcy) may directly cause the
molecular pathology underlying AD, and the use of
vitamins to lower tHcy may have a role in the
prevention of AD (64). Adequate intake of folatecontaining foods and probably relatively good
nutritional intake results in a reduction in tHcyinduced production and/or accumulation of Aβ
processes subsequently lead to AD (65). Thus, this
study supports the potential role of B vitamins in
improvement of the biochemical markers investigated
in our study.

AD sufferers have been found to have a lack of
the enzyme responsible for converting choline into
acetylcholine within the brain (66). Acetylcholine
(ACh) is a neurotransmitter derived from choline
and coenzyme A. Nervous tissue cannot synthesize
choline, which is ultimately derived from the diet
and delivered to neurons through the blood stream.
ACh released from cholinergic synapses is
hydrolyzed by AChE into choline and acetyl
coenzyme A. Approximately 50% of choline derived
from ACh hydrolysis is recovered through a high
affinity transporter. As a consequence of this,
neurons require a further supply of choline for ACh
synthesis (67). Lecithin is a major dietary source of
choline. Replacement of cholinergic function may be
of therapeutic benefit to AD patients. Different
approaches proposed that the intervention with
AChE precursor stimulates ACh release via
muscarinic or nicotinic receptor agonists or AChE
inhibition (68) have a potential role in management
of AD. By this way, treatment of Al-intoxicated rats
with lecithin produces moderate effect on the
examined neuronal biochemical marker in the
current study.
The combined therapy including CoQ10, vitamin
B complex, and lecithin exhibits the most pronounced
effect as compared to the other treatments in
improving the studied biochemical parameters related
to the neurological damage, characteristic of AD. This
finding could be interpreted as that vitamin B
complex is a potent antioxidant agent, which
scavenges free radicals, reduces the oxidative stress,
and enhances the antioxidant defense system. CoQ10
initiates the reaction involves in the production of
acetyl Co-A. Lecithin represents the source of choline,
the precursor of Ach, in the presence of acetyl Co-A.
Therefore, we suggest that the synergestic effect of
these nutraceuticals resulted in the observed
neuroprotective action of the selected combined
therapy.
Histopathological investigation showed that AlCl3
administration causes neuronal degeneration and
brain necrosis in concomitant with the appearance of
neurofibrillary tangle-bearing neurons. This finding
agrees with the previous report of Lopez and Becker,
and Sergeant et al. (69,70). These histopathological
features are the hallmarks that characterize AD.
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Treatment of Al-intoxicated rats with CoQ10 showed
the appearance of more or less normal structure of
most neurons. Necrosis of some neurons was also
observed. These results are consistent with those of
Ostrowski (62), who reported that CoQ10 diminishes
neuronal injury in the hippocampal region. Vitamin B
administration to Al-intoxicated rats revealed the
neurons in healthy appearance with small condensed
surrounding cells. Necrosis of some neurons still
appeared. These findings are supported by Hoane et
al. (71). Al intoxicated rats treated with lecithin
showed some degree of degenerative neurons. This
result is in agreement with Muma and Rowell (72).
The combined therapy improved the structure and

viability of the brain cells with the exception of the
appearance of some pale supporting cells in the brain
of male rats.
In conclusion, supplementation with the selected
nutraceuticals in the current study significantly
modulated the biochemical markers of Alintoxicated rats. These findings were well
documented by histopathological investigations.
Therefore, we suggest that the synergistic effect of
CoQ10, vitamin B complex, and lecithin in the
combined therapy results in marked neuroprotective
action rather than the individual treatment with
either one in reducing the progressive neurological
damage characterizing AD.
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